Clinical Report: Nicotinamide Mononucleotide and Endothelial Hyperpermeability
Overview
This study demonstrates that nicotinamide mononucleotide (NMN) protects endothelial cells from hyperpermeability induced by IL-1β through the inhibition of VE-cadherin degradation. The findings suggest that NMN's protective effects are mediated via the NAD+-SIRT1 axis, highlighting its potential therapeutic role in inflammatory vascular diseases.
Background
Endothelial dysfunction, particularly increased permeability, is a key factor in various inflammatory vascular diseases, including atherosclerosis and sepsis. Understanding the mechanisms that contribute to endothelial barrier integrity is crucial for developing targeted therapies. This study investigates the protective role of NMN, an NAD+ precursor, against macrophage-derived inflammatory stimuli.
Data Highlights
Condition
Effect of NMN
M1 Macrophage Co-culture
Increased HUVEC permeability
NMN Pretreatment
Attenuated hyperpermeability
IL-1β Induction
Promoted VE-cadherin degradation
SIRT1 Inhibition
Abrogated NMN effects
Key Findings
NMN pretreatment significantly reduced endothelial hyperpermeability induced by M1 macrophages.
IL-1β released from M1 macrophages was identified as a primary contributor to endothelial hyperpermeability.
NMN inhibited the degradation of VE-cadherin, a critical protein for endothelial barrier integrity.
The protective effects of NMN were linked to the inhibition of the NF-κB signaling pathway.
Other NAD+ precursors also demonstrated protective effects against IL-1β-induced hyperpermeability.
Clinical Implications
The findings suggest that NMN may serve as a potential therapeutic agent for preventing endothelial dysfunction in inflammatory vascular diseases. Clinicians should consider the role of NAD+ precursors in managing conditions characterized by endothelial hyperpermeability.
Conclusion
This study highlights the importance of the NAD+-SIRT1 axis in maintaining endothelial barrier integrity and suggests that NMN could be a valuable intervention in inflammatory vascular conditions.
Revised American Heart Association statement urges a shift toward plant-based protein and flags ongoing uncertainty in fat and alcohol recommendations.
